Timothy A. Horwedel
Research Subjects
Timothy A. Horwedel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Daniel C. Brennan
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publications - James N. Fleming
College of Medicine, Medical University of South Carolina, Charleston, South Carolina
2 shared publications - Angela Q. Maldonado
Hansa Biopharma AB, Lund, Sweden
1 shared publication Barrett R. Crowther
University of Colorado Health Aurora Colorado USA
1 shared publication- Bharath R. Ravichandran
Department of Pharmacy, University of Maryland Medical Center, Baltimore, Maryland
1 shared publication - Christin Rogers Marks
Novo Nordisk Inc, Plainsboro, NJ USA
1 shared publication
Latest Publications
- Open Access
- 11 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 2011-2012
Response to: The expanded role of the transplant pharmacist: A 10-year follow-up by Lichvar et al
- 11 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (12) , 2011-2012
Open AccessResponse to: The expanded role of the transplant pharmacist: A 10-year follow-up by Lichvar et al
- 28 April 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (9) , 1144-1153
Survey‐based assessment of shifting trends in first solid organ transplant pharmacist jobs
- 28 April 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (9) , 1144-1153
Survey‐based assessment of shifting trends in first solid organ transplant pharmacist jobs
- 24 January 2015
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 41 (1) , 37-47
Single-Dose Rituximab for Recurrent Glomerulonephritis Post-Renal Transplant
Background/Aims: Post-renal transplant recurrent glomerulonephritis (GN) contributes to allograft loss. Rituximab treatment has been used in a multidose strategy with variable efficacy and toxicity. We investigated a novel single-dose approach. Methods: A single center, retrospective, cohort study was conducted between January 1998 and April 2012 among renal allograft recipients with recurrent GN treated with rituximab (cases) or without (controls). The primary outcome was complete response (CR, urine protein/creatinine ratio (UP/C) 50% reduction in UP/C), response relapse, treatment-response by GN type, acute rejection incidence, time to graft loss, and infection incidence. Results: The median dose of rituximab was 200 mg per patient. Of 20 rituximab cases and 13 controls, CR was achieved in eight (40%) versus four (31%), respectively (p = 0.72). Three subjects in each group achieved PR (p = 0.66). Response relapse was similar between the two groups (p = 0.47). Significantly more subjects with recurrent membranous nephropathy (MN) achieved CR with rituximab treatment (p = 0.029). Acute rejection was lower in the rituximab group versus controls (n = 0 vs. 4; p = 0.046). The mean time to graft loss was much later in the rituximab group (35 months, (95% CI 33-37)) versus controls (29 months, (95% CI 24-35)) at 36 months (p = 0.04). There was no infection increase in rituximab-treated subjects (p = 0.16). Conclusion: Single-dose rituximab for treatment of recurrent GN was associated with less subsequent rejection and longer time to graft loss without increased infection, but was no more effective than regimens not using rituximab at 36-months except those with recurrent membranous GN.
- 24 January 2015
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 41 (1) , 37-47
Single-Dose Rituximab for Recurrent Glomerulonephritis Post-Renal Transplant
Background/Aims: Post-renal transplant recurrent glomerulonephritis (GN) contributes to allograft loss. Rituximab treatment has been used in a multidose strategy with variable efficacy and toxicity. We investigated a novel single-dose approach. Methods: A single center, retrospective, cohort study was conducted between January 1998 and April 2012 among renal allograft recipients with recurrent GN treated with rituximab (cases) or without (controls). The primary outcome was complete response (CR, urine protein/creatinine ratio (UP/C) 50% reduction in UP/C), response relapse, treatment-response by GN type, acute rejection incidence, time to graft loss, and infection incidence. Results: The median dose of rituximab was 200 mg per patient. Of 20 rituximab cases and 13 controls, CR was achieved in eight (40%) versus four (31%), respectively (p = 0.72). Three subjects in each group achieved PR (p = 0.66). Response relapse was similar between the two groups (p = 0.47). Significantly more subjects with recurrent membranous nephropathy (MN) achieved CR with rituximab treatment (p = 0.029). Acute rejection was lower in the rituximab group versus controls (n = 0 vs. 4; p = 0.046). The mean time to graft loss was much later in the rituximab group (35 months, (95% CI 33-37)) versus controls (29 months, (95% CI 24-35)) at 36 months (p = 0.04). There was no infection increase in rituximab-treated subjects (p = 0.16). Conclusion: Single-dose rituximab for treatment of recurrent GN was associated with less subsequent rejection and longer time to graft loss without increased infection, but was no more effective than regimens not using rituximab at 36-months except those with recurrent membranous GN.
- 15 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 553
Ureteral Stent Placement Increases the Risk of BK Viremia in the First Year After Kidney Transplantation: A Validation Study.
- 15 July 2014
- Published by Wolters Kluwer Health in Transplantation
- Vol. 98, 553
Ureteral Stent Placement Increases the Risk of BK Viremia in the First Year After Kidney Transplantation: A Validation Study.